AstraZeneca Pharma India Limited (IN:ASTRAZEN)
:ASTRAZEN
Want to see IN:ASTRAZEN full AI Analyst Report?
Top Page
AstraZeneca Pharma India Limited
(ASTRAZEN)
Select Model
Select Model
Rating:59Neutral
Price Target:
₹9,045.00
▲(7.27% Upside)
Action:Downgraded
Date:05/28/26
The score is held back primarily by weakened FY2026 cash flow and margin compression despite strong revenue growth and a low-leverage balance sheet. Technicals are supportive in the near term, but the very high P/E and low dividend yield make valuation a meaningful headwind.
Positive Factors
Revenue Growth / Commercial Momentum
Meaningful revenue scaling (FY2026 growth 13.6%) indicates expanding market penetration and sustained demand for its branded specialty and chronic therapies. Durable top-line growth supports investment in sales, launches and longer-term market share even amid margin variability.
Negative Factors
Margin Compression
Gross margin plunged to 26.5% and EBIT margin to 10.3%, suggesting cost pressure or adverse mix. Persistent margin compression would erode EBITDA and free cash flow, constraining reinvestment in high-value specialty launches and reducing long-term profitability resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth / Commercial Momentum
Meaningful revenue scaling (FY2026 growth 13.6%) indicates expanding market penetration and sustained demand for its branded specialty and chronic therapies. Durable top-line growth supports investment in sales, launches and longer-term market share even amid margin variability.
Read all positive factors
AstraZeneca Pharma India Limited (ASTRAZEN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹206.10B
Dividend Yield0.35%
Average Volume (3M)602.00
Price to Earnings (P/E)110.0
Beta (1Y)0.71
Revenue Growth32.59%
EPS Growth62.01%
CountryIN
Employees940
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)79.66
Shares Outstanding25,000,000
10 Day Avg. Volume682
30 Day Avg. Volume602
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)22.24
Price to Sales (P/S)8.53
P/FCF Ratio6.05K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AstraZeneca Pharma India Limited Business Overview & Revenue Model
Company Description
AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The comp...
How the Company Makes Money
AstraZeneca Pharma India Limited makes money primarily by selling branded prescription pharmaceutical products in India. Its core revenue stream is income from operations generated through domestic sales of AstraZeneca-branded medicines across its...
AstraZeneca Pharma India Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
86
Very Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.03B | 22.76B | 17.13B | 12.96B | 10.03B | 8.06B |
| Gross Profit | 8.39B | 6.02B | 7.13B | 6.22B | 5.78B | 4.48B |
| EBITDA | 3.16B | 2.85B | 1.98B | 2.36B | 1.51B | 1.01B |
| Net Income | 1.99B | 1.88B | 1.16B | 1.62B | 992.90M | 616.00M |
Balance Sheet | ||||||
| Total Assets | 16.15B | 19.89B | 15.18B | 10.78B | 9.85B | 8.57B |
| Cash, Cash Equivalents and Short-Term Investments | 4.10B | 4.49B | 5.53B | 5.06B | 5.00B | 4.48B |
| Total Debt | 347.90M | 1.11B | 357.30M | 45.90M | 72.14M | 86.30M |
| Total Liabilities | 8.16B | 11.16B | 7.48B | 3.66B | 3.96B | 3.45B |
| Stockholders Equity | 7.99B | 8.73B | 7.70B | 7.12B | 5.89B | 5.11B |
Cash Flow | ||||||
| Free Cash Flow | -660.20M | 32.10M | 636.10M | 171.10M | 497.70M | 911.80M |
| Operating Cash Flow | -657.30M | 68.20M | 653.60M | 278.70M | 582.90M | 1.01B |
| Investing Cash Flow | 135.40M | -33.40M | 308.00M | 217.40M | 181.10M | 47.40M |
| Financing Cash Flow | -845.60M | -919.00M | -655.90M | -443.80M | -244.80M | -94.60M |
AstraZeneca Pharma India Limited Technical Analysis
Negative
8431.70
Price Trends
8401.58
Negative
8491.19
Negative
8749.98
Negative
Market Momentum
-39.75
Positive
40.89
Neutral
10.84
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTRAZEN, the sentiment is Negative. The current price of 8431.7 is below the 20-day moving average (MA) of 8565.13, above the 50-day MA of 8401.58, and below the 200-day MA of 8749.98, indicating a bearish trend. The MACD of -39.75 indicates Positive momentum. The RSI at 40.89 is Neutral, neither overbought nor oversold. The STOCH value of 10.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTRAZEN.
AstraZeneca Pharma India Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹633.22B | 27.53 | ― | 0.80% | 13.48% | 6.18% | |
69 Neutral | ₹359.26B | 34.70 | ― | 2.16% | 1.93% | 11.69% | |
60 Neutral | ₹613.28B | 45.05 | ― | 0.24% | 27.48% | 30.05% | |
59 Neutral | ₹206.10B | 109.99 | ― | 0.35% | 32.59% | 62.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ASTRAZEN
AstraZeneca Pharma India Limited
8,243.90
-1,925.51
-18.93%
IN:ALKEM
Alkem Laboratories Ltd.
5,296.05
475.91
9.87%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,120.70
-1,162.41
-35.41%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,173.20
494.67
29.47%
AstraZeneca Pharma India Limited Corporate Events
AstraZeneca Pharma India Confirms SEBI Demat Compliance for March 2026
Apr 29, 2026
AstraZeneca Pharma India Limited has disclosed that its registrar and transfer agent, Integrated Registry Management Services, has issued a certificate confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulat...
AstraZeneca Pharma India Wins New Approval for Calquence Use in Untreated CLL and SLL
Apr 10, 2026
AstraZeneca Pharma India has received permission from India’s Central Drugs Standard Control Organisation to import Acalabrutinib 100 mg tablets, marketed as Calquence, for an additional indication in combination with venetoclax with or with...
AstraZeneca Pharma India bolsters oncology and market access leadership
Mar 31, 2026
AstraZeneca Pharma India Limited has strengthened its leadership team by appointing clinical oncologist Dr. Shashank Srinivasan as Medical Director for its Oncology Business Unit, effective April 1, 2026. Dr. Srinivasan brings extensive experience...
AstraZeneca Pharma India Clears Related-Party Deals via Postal Ballot
Mar 31, 2026
AstraZeneca Pharma India Limited has announced that ordinary resolutions seeking shareholder approval for material related-party transactions have been passed by non-related members through a postal ballot, with the requisite majority. The company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.